This content is machine translated GLP-1 receptor agonists in type 2 diabetes Nephroprotection with semaglutide and liraglutide – direct or indirect effects? In a post-hoc analysis of large randomized placebo-controlled trials, HbA1c and body weight and blood pressure were examined as mediator variables regarding the renal protective effects of the GLP-1 receptor…
View Post 4 min This content is machine translated Diabetic nephropathy SGLT-2 inhibitor slows decline in glomerular filtration rate For the first time, a targeted therapy for diabetic kidney disease is available. In the CREDENCE study, canagliflozin resulted in a clinically relevant and statistically significant risk reduction for renal…
View Post 2 min This content is machine translated Schwartz-Bartter syndrome Effectively balancing electrolyte imbalances: focus on osmoregulation Nausea, vomiting, headaches and muscle cramps may also result from water retention. In Schwarzt-Bartter syndrome, this is triggered by ADH accumulation. The cause is usually small cell lung cancer, but…
View Post 5 min This content is machine translated Diabetic nephropathy Gliflozines may slow progression of renal failure Nephropathy as a late complication of diabetes is a common cause of renal failure requiring dialysis. In the CREDENCE trial, SGLT-2 inhibitors slowed the progression of renal dysfunction in diabetic…
View Post 3 min This content is machine translated Renal failure Treat hypertension effectively to protect the kidney There is a reciprocal relationship between elevated blood pressure and kidney disease. Therefore, consistent hypertension therapy is particularly important in the presence of impaired renal performance. This is because intensive…
View Post 2 min This content is machine translated SGLT2 inhibitor convinces Dapagliflozin may score well in nephro- and cardioprotection Patients with diabetic nephropathy can now be effectively treated with SGLT2 inhibitors. They are also said to have cardioprotective effects. Dapagliflozin is now the first and only antidiabetic agent approved…
View Post 7 min This content is machine translated Diabetes Management Nephro- and cardioprotection as an interdisciplinary challenge Early detection and treatment of renal dysfunction and cardiovascular risk factors in type 2 diabetes mellitus is essential. Experts see a need for action in this area, especially with regard…
View Post 3 min This content is machine translated Hyperkalemia How the Guideline Comes to the Bedside: Hyperkalemia Management Up to Date Patients with chronic heart or kidney failure often suffer from hyperkalemia. The use of RAAS inhibitors in particular may increase the risk of this life-threatening electrolyte disturbance. Therefore, therapy of…
View Post 3 min This content is machine translated Diabetic kidney disease Canagliflozin approved in fast track for diabetic nephropathy Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to…
View Post 3 min This content is machine translated Chronic renal failure Dapagliflozin meets primary endpoints ahead of schedule The Phase III DAPA-CKD study will be terminated earlier than planned due to proven efficacy in patients with chronic renal failure. Dapagliflozin is the first SGLT2 inhibitor to show meaningful…
View Post 6 min This content is machine translated Type 2 diabetes: SGED Recommendations 2020 Update Cardiovascular risk stratification and personalized therapy. When prescribing antidiabetic therapy, other criteria are relevant today in addition to blood glucose control. The cardiac benefit of SGLT2 inhibitors and GLP1 analogues has been incorporated into international guidelines…
